Healthcare / BiotechnologySwiss
$27.10
+0.40 (+1.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-18.9M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$158M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-36.5%
↓Gross Margin
-386.6%
↓Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-2770.3%
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $800000.0 · net income $-21.8M · FCF $-22.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $800000.00 | $800000.00 | — |
| Net Income | $-21.8M | $-21.8M | $-18.7M |
| EBITDA | $-20.4M | $-20.4M | $-17.4M |
| EPS | -3.89 | -3.89 | -3.16 |
| Gross Margin | -386.6% | -386.6% | — |
| Operating Margin | -2495.4% | -2495.4% | — |
| Net Margin | -2728.8% | -2728.8% | — |
| Balance Sheet | |||
| Debt/Equity | 0.36 | 0.36 | 1.59 |
| Current Ratio | 10.10 | 10.10 | — |
| Cash Flow | |||
| Free Cash Flow | $-22.2M | $-22.2M | $-15.6M |
| Returns | |||
| ROE | -36.5% | -36.5% | -175.2% |
| Valuation | |||
| P/B | 2.54 | 2.54 | — |
| Growth & Yield | |||
| EPS Growth | -22.9% | -22.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.16 → -3.89
Residual
-22.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.